This company has been marked as potentially delisted and may not be actively trading. NYSE:ISR Isoray (ISR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Isoray Stock (NYSE:ISR) 30 days 90 days 365 days Advanced Chart Get Isoray alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.28▼$0.4252-Week Range N/AVolume145,000 shsAverage Volume290,697 shsMarket Capitalization$54.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA. Read More Receive ISR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Isoray and its competitors with MarketBeat's FREE daily newsletter. Email Address ISR Stock News HeadlinesFrench ISR Label Revamp ReportNovember 22, 2023 | morningstar.comMWhy IsoRay (ISR) Is Plunging TodayApril 24, 2023 | thestreet.com10 Cheap Stocks Ready to ExplodeRemember when Nvidia was trading at $60? Yeah, me too. Painful, right? While early investors turned every $10,000 into $100,000+, most of us watched from the sidelines, thinking we'd already missed the boat. Here's the thing though... The AI revolution isn't over. It's just getting started.July 9 at 2:00 AM | TradingTips (Ad)Why IsoRay (ISR) Stock Is Surging TodayMarch 16, 2023 | thestreet.comIsoRay (ISR) Reports Q2 Loss, Misses Revenue EstimatesFebruary 16, 2023 | finance.yahoo.comPerspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022February 16, 2023 | finance.yahoo.comIsoray, Inc.: Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.February 8, 2023 | finanznachrichten.deIsoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.February 7, 2023 | finance.yahoo.comSee More Headlines ISR Stock Analysis - Frequently Asked Questions How were Isoray's earnings last quarter? Isoray, Inc. (NYSE:ISR) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.01. The company had revenue of $2.56 million for the quarter, compared to analysts' expectations of $2.58 million. Isoray had a negative net margin of 115.91% and a negative trailing twelve-month return on equity of 17.12%. What other stocks do shareholders of Isoray own? Based on aggregate information from My MarketBeat watchlists, some other companies that Isoray investors own include Brainstorm Cell Therapeutics (BCLI), OPKO Health (OPK), Tesla (TSLA), Meta Platforms (META), Tonix Pharmaceuticals (TNXP) and Nano Dimension (NNDM). Company Calendar Last Earnings11/10/2021Today7/08/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:ISR CIK728387 Webisoray.com Phone(509) 375-1202Fax509-267-3670EmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.27 million Net Margins-115.91% Pretax Margin-91.45% Return on Equity-17.12% Return on Assets-16.15% Debt Debt-to-Equity RatioN/A Current Ratio14.38 Quick Ratio13.99 Sales & Book Value Annual Sales$10.80 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / BookN/AMiscellaneous Outstanding Shares142,110,000Free Float138,674,000Market Cap$54.57 million OptionableNot Optionable Beta1.48 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSE:ISR) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Isoray, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Isoray With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
